神威藥業(02877.HK)2022年度純利升29.8%至7.23億元 中藥配方顆粒銷售額突破11億元
格隆匯3月30日丨神威藥業(02877.HK)公佈2022年度業績,期內集團實現營業額39.51億元人民幣(單位下同),同比增長22.6%;毛利29.38億元,同比增長21.9%,毛利率由上年同期的74.8%輕微降至74.4%;公司擁有人應占年內溢利7.23億元,同比增長29.8%;每股基本盈利96分,宣派2023年第一次中期股息每股31分,連同2022年第二次中期股息11分,與2022財年利潤相關的股息共計42分,派息率為43.8%。
中藥配方顆粒於年內繼續成為集團業務增長的火車頭,其銷售額突破11億元,較去年上升59.3%,銷售額位列全國中藥配方顆粒行業上巿公司前五強。集團中藥配方顆粒擁有多個知識產權和發明專利,多年來承擔國家和省級多項科研專案,亦是中藥配方顆粒國家標準制定參與者之一。於年內集團“中藥配方顆粒智慧化製造及品質控制研究”榮獲“2022年度中華中醫藥學會科技進步二等獎”。
市場開放後,中藥配方顆粒的使用由二級及以上中醫院放寬至各符合條件的醫療機構。根據《“十四五”中醫藥發展規劃》,各級醫療機構開展中醫藥服務受到國家政策鼓勵,隨着中藥配方顆粒國標數量逐漸增多,醫療機構處方需求覆蓋將更全面,中藥配方顆粒市場規模將持續擴大。截至2022年底,集團中藥配方顆粒已於2個直轄市和13個省份掛網。2023年,集團將以“深耕河北、壯大雲南、開發四省、加密基層”為優先的戰略部署,穩步發展中藥配方顆粒全國市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.